1-(2,6-difluorophenyl)cyclobutane-1-carbonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2,6-difluorophenyl)cyclobutane-1-carbonitrile
• 化学式: C₁₁H₉F₂N
• mdl: MFCD11036673
• 分子量: 193.196
• InChiKey: RVWMRQGDXZRNJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2,6-difluorophenyl)cyclobutane-1-carbonitrile 在 四丁基溴化铵 、 双氧水 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 18.0h， 以47.2%的产率得到1-(2,6-difluorophenyl)cyclobutane-1-carboxamide
  参考文献：
  名称：

  KR2017/43091

  摘要：

  公开号：
• 作为产物：
  描述：

  2,6-二氟苯乙腈 、 1,3-二溴丙烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.5h， 以37.1%的产率得到1-(2,6-difluorophenyl)cyclobutane-1-carbonitrile
  参考文献：
  名称：

  KR2017/43091

  摘要：

  公开号：

文献信息

• OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Chong Kun Dang Pharmaceutical Corp.

  公开号：EP3362445A1

  公开（公告）日：2018-08-22
• [EN] OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS D'OXADIAZOLE AMINE UTILISÉS EN TANT QU'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2017065473A1

  公开（公告）日：2017-04-20

  The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.
• KR2017/43091
  申请人：——

  公开号：——

  公开（公告）日：——
• Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)
  作者：Wu He、Bin Zhou、Weijia Liu、Meizi Zhang、Zhenhua Shen、Zhifu Han、Qingwei Jiang、Qinghua Yang、Chuanjun Song、Ruiyong Wang、Tianhui Niu、Shengna Han、Lirong Zhang、Jie Wu、Feima Guo、Renbin Zhao、Wenquan Yu、Jijie Chai、Junbiao Chang

  DOI：10.1021/acs.jmedchem.5b00702

  日期：2015.9.24

  N-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylcyclobutanecarboxamide (N-CDPCB, 1a) is found to be an inhibitor of the fat mass and obesity associated protein (FTO). The crystal structure of human FTO with la reveals a novel binding site for the FTO inhibitor and defines the molecular basis for recognition by FTO of the inhibitor. The identification of the new binding site offers new opportunities for further development of selective and potent inhibitors of FTO, which is expected to provide information concerning novel therapeutic targets for treatment of obesity or obesity-associated diseases.